EMA, FDA To Address Quality Issues For PRIME/Breakthrough Designation Products

Experience with early access schemes in the EU and the US – i.e., PRIME and breakthrough therapy designation – has shown that sponsors face challenges in complying with quality and manufacturing data requirements. 

PS1807_Case Study_547542223_1200.jpg
Workshop Will Include Specific Industry Case Studies And Discussion On Experience Till Date • Source: Shutterstock

The European Medicines Agency and the US Food and Drug Administration are set to discuss the quality and manufacturing-related problems that sponsors face for drugs developed under the regulators’ early access programs, PRIME (priority medicines) and breakthrough therapy designation (BTD) respectively.

The discussion will take place at a workshop on Nov. 26 at the EMA's London headquarters, where the EU...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography